Lifesci Capital Predicts Immunome FY2024 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($1.83) for the year. Lifesci Capital has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q4 2024 earnings at ($0.43) EPS.

Separately, Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Monday, March 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $27.17.

Immunome Stock Down 1.8 %

Shares of NASDAQ:IMNM opened at $8.77 on Friday. The firm has a market cap of $699.64 million, a P/E ratio of -1.08 and a beta of 1.93. Immunome has a 12-month low of $8.39 and a 12-month high of $26.70. The business has a fifty day simple moving average of $9.98 and a 200 day simple moving average of $11.80.

Insider Buying and Selling at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently modified their holdings of IMNM. Enavate Sciences GP LLC bought a new position in shares of Immunome during the 4th quarter worth approximately $36,939,000. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after purchasing an additional 624,045 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the period. Granahan Investment Management LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $3,337,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Immunome by 2,696.5% in the 4th quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after purchasing an additional 304,700 shares during the period. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.